Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neem Mouthrinse is an investigational herbal mouthwash containing an extract of neem leaf (*Azadirachta indica*), developed by the Medical University of South Carolina (MUSC) for the management of radiotherapy-induced oral mucositis. Oral mucositis is a common and debilitating side effect of radiation therapy in head and neck cancer patients, characterized by inflammation and ulceration of the oral mucosa. The therapeutic potential of neem leaf extract in this condition is attributed to its rich content of bioactive compounds, including limonoids like nimbin and azadirachtin, which exhibit potent anti-inflammatory, antioxidant, and antimicrobial activities. The mechanism of action involves the suppression of pro-inflammatory signaling pathways, such as NF-kappaB, and the reduction of oxidative stress, thereby protecting the mucosal lining and promoting healing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neem Mouthrinse.